( THE WOODLANDS Texas--(BUSINESS WIRE)--...)Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits,Potential for New Approach to the Treatment and Prevention of,Breast Cancer,Health

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that an article has been published in the July 1, 2007 issue of Oncology Reports indicating a potential for a new approach to the treatment of breast cancer using Proellex. The article reviews the findings from a study conducted in an accepted in vivo rat model of breast cancer. The study was conducted in collaboration with scientists from the University of Illinois at Chicago College of Medicine and IIT Research Institute.

In the published report, the effects of Proellex were evaluated in a rat model wherein breast tumors are induced via a known carcinogenic compound. In the study, the hormone progesterone was shown to increase the number of growing tumors. Conversely, the administration of Proellex exhibited an inhibitory effect resulting in not only a regression of the size of tumors but also a suppression of the development of new tumors.

Approximately 200,000 American women were diagnosed with breast cancer in 2005. Women whose primary lesions contain both estrogen and progesterone receptors are typically treated with anti-estrogens or aromatase inhibitors which inhibit the synthesis of estrogen. Progestins (progesterone like compounds) have been shown to increase the incidence of spontaneous mammary tumors in dogs and mice. Reports from the Women's Health Initiative showed a small but clearly higher risk of breast cancer in women taking hormone replacement therapy that included a progestin.

In the past, anti-progestins such as Proellex have been postulated to be of potential benefit in the treatment of breast cancer. Unfortunately, most of the drugs in the class have significant anti-glucocorticoid activity which would prohibit their chronic use. In human studies conducted by Repros to date, Proellex has exhibited little anti-glucocorticoid activity in humans.

Proellex may rep
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
9. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood